LIFE SCIENCE

We invest in early-stage companies, founded on innovative research-based technologies within pharma and medtech, with compelling value propositions serving unmet medical needs. We look for well-defined development plans with clear value inflection points, enabling robust returns on investment. 

CLEAN TECH ENERGY AND TECHNOLOGY

We invest in leading early stage science and technology based companies with technologies that can make the world a better place and accelerate the transition to a 100% renewable energy system. We look for exceptional entrepreneurs and breakthrough innovations that may have an disruptive impact on industries and markets and create value for individuals, society, industry and investors. 

Sarsia is a Norwegian early stage Venture Capital fund manager investing in technology companies within the energy / technology and biotechnology / life science sectors.

BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB

BerGenBio announces the the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for bemcentinib in combination with and anti-PD-(L)1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer (NSCLC)...

APIM THERAPEUTICS COMPLETES PRIVATE PLACEMENT AND ENTERS PHASE-2

APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The proceeds from the investment round will be used to conduct a Phase-2 study in sarcoma. The study will be initiated and...

APIM Therapeutics announces IND for ATX-101 in Ovarian Cancer

APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...

Arxx Therapeutics Secures NOK110

APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...

Heimdall Power raises NOK 155 mill

The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power AS to help accelerate the company's growth strategy.  The total transaction was 155mNOK involving existing investors...

Coegin Pharma AB listed on Nordic SME

Sarsia Seed portfolio company Coegin Pharma AB was yesterday listed on Nordic SME stock exchange.  (Ticker: COEGIN) Read more

Vaccibody AS Lists on Oslo Stock Exchange

Sarsia Seed portfolio company Vaccibody AS - was today listed on Oslo Stock Exchange´s Merkur Markets list.                                                                                                                                                                 ...

Vaccibody enters into worldwide license and collaboration agreement with Genentech

It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition.             ...

Vaccibody and Nektar Therapeutics Announce First Patient Dosed in collaborative Phase 1/2a Study

Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR)  announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody's...

Vaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer

Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...